Information Provided By:
Fly News Breaks for November 2, 2018
BDSI
Nov 2, 2018 | 11:10 EDT
H.C. Wainwright analyst Oren Livnat said the latest IQVIA data, through the week ending October 26, for prescription volume trends for Belbuca "easily hit a new all-time high," noting that prescriptions for BioDelivery Sciences' film for chronic pain are accelerating upward. He added that current trends come ahead of additional PBM formulary wins. The analyst, who said that he is "comfortable" with his "Street-high" $80M Belbuca sales estimate in 2019, keeps a Buy rating on BioDelivery Sciences shares.
News For BDSI From the Last 2 Days
There are no results for your query BDSI